Back to search
FDAFDA · Food and drugs·Recall number D-168-2013

EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA

Published March 6, 2013 · Recall initiated: December 17, 2012

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent; bupivacaine

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Recall details

Manufacturer
Pacira Pharmaceuticals, Inc.
Distributor
Nationwide distribution: AZ, DC, FL, GA, MA, NJ, NY, OH, and TX.
Lot
Lot #11-2005 Control #23542 Manufacture Date: 05Dec11 2011-L-009
Risk classification
Class II
Area (FDA)
drug
Country
United States

Sell products like this?

Recalert watches your whole catalog for recalls like this one, automatically.

Start free — no card